omalizumab [Omalizumab]

tematický
112
Termíny

Xolair

 

Xolair

Perzistentní odkaz   https://www.medvik.cz/link/D000069444
Definice

An anti-IgE, recombinant, humanized monoclonal antibody which specifically binds to the C epsilon3 domain of IMMUNOGLOBULIN E, the site of high-affinity IgE receptor binding. It inhibits the binding of IgE to MAST CELLS and BASOPHILS to reduce the severity of the allergic response and is used in the management of persistent allergic ASTHMA.

DUI
D000069444 MeSH Prohlížeč
CUI
M0387411
CAS
Immunoglobulin G, anti-(human immunoglobulin E Fc region)(human-mouse monoclonal E25 clone pSVIE26 gamma-chain), disulfide with human-mouse monoclonal E25 clone pSVIE26 kappa-chain, dimer
Historická pozn.
2016 (2001)
Veřejná pozn.
2016; OMALIZUMAB was indexed under ANTIBODIES, ANTI-IDIOTYPIC and ANTIBODIES, MONOCLONAL, HUMANIZED 2011-2015; and under ANTIBODIES, MONOCLONAL 2001-2011

D Chemikálie a léčiva
D12.776 proteiny 2 575
D12.776.124 krevní proteiny 909
D12.776.124.486 imunoproteiny 14
D12.776.124.486.485 imunoglobuliny 1 486
D12.776.124.486.485.114 protilátky 1 815
D12.776.124.486.485.114.071 protilátky anti-idiotypické 61
D12.776.124.486.485.114.071.500 omalizumab 112
D12.776.124.486.485.114.224 monoklonální protilátky 4 626
D12.776.124.486.485.114.224.060 humanizované monoklonální protilátky 2 783
D12.776.124.486.485.114.224.060.125 abciximab 14
D12.776.124.486.485.114.224.060.250 adalimumab 346
D12.776.124.486.485.114.224.060.313 alemtuzumab 123
D12.776.124.486.485.114.224.060.344 basiliximab 2
D12.776.124.486.485.114.224.060.375 bevacizumab 445
D12.776.124.486.485.114.224.060.438 brentuximab vedotin 40
D12.776.124.486.485.114.224.060.500 certolizumab pegol 47
D12.776.124.486.485.114.224.060.750 cetuximab 185
D12.776.124.486.485.114.224.060.766 daklizumab 6
D12.776.124.486.485.114.224.060.782 denosumab 150
D12.776.124.486.485.114.224.060.790 gemtuzumab 16
D12.776.124.486.485.114.224.060.794 inotuzumab ozogamicin 11
D12.776.124.486.485.114.224.060.798 ipilimumab 253
D12.776.124.486.485.114.224.060.813 natalizumab 156
D12.776.124.486.485.114.224.060.829 nivolumab 427
D12.776.124.486.485.114.224.060.844 omalizumab 112
D12.776.124.486.485.114.224.060.860 palivizumab 12
D12.776.124.486.485.114.224.060.864 panitumumab 57
D12.776.124.486.485.114.224.060.866 ramucirumab 1
D12.776.124.486.485.114.224.060.868 ranibizumab 61
D12.776.124.486.485.114.224.060.875 trastuzumab 268
D12.776.124.486.485.114.224.060.937 ustekinumab 120
D12.776.124.790 sérové globuliny 61
D12.776.124.790.651 imunoglobuliny 1 486
D12.776.124.790.651.114 protilátky 1 815
D12.776.124.790.651.114.071 protilátky anti-idiotypické 61
D12.776.124.790.651.114.071.500 omalizumab 112
D12.776.124.790.651.114.224 monoklonální protilátky 4 626
D12.776.124.790.651.114.224.060 humanizované monoklonální protilátky 2 783
D12.776.124.790.651.114.224.060.125 abciximab 14
D12.776.124.790.651.114.224.060.250 adalimumab 346
D12.776.124.790.651.114.224.060.375 alemtuzumab 123
D12.776.124.790.651.114.224.060.407 basiliximab 2
D12.776.124.790.651.114.224.060.438 bevacizumab 445
D12.776.124.790.651.114.224.060.469 brentuximab vedotin 40
D12.776.124.790.651.114.224.060.500 certolizumab pegol 47
D12.776.124.790.651.114.224.060.750 cetuximab 185
D12.776.124.790.651.114.224.060.766 daklizumab 6
D12.776.124.790.651.114.224.060.782 denosumab 150
D12.776.124.790.651.114.224.060.790 gemtuzumab 16
D12.776.124.790.651.114.224.060.794 inotuzumab ozogamicin 11
D12.776.124.790.651.114.224.060.798 ipilimumab 253
D12.776.124.790.651.114.224.060.813 natalizumab 156
D12.776.124.790.651.114.224.060.829 nivolumab 427
D12.776.124.790.651.114.224.060.844 omalizumab 112
D12.776.124.790.651.114.224.060.860 palivizumab 12
D12.776.124.790.651.114.224.060.864 panitumumab 57
D12.776.124.790.651.114.224.060.866 ramucirumab 1
D12.776.124.790.651.114.224.060.868 ranibizumab 61
D12.776.124.790.651.114.224.060.875 trastuzumab 268
D12.776.124.790.651.114.224.060.937 ustekinumab 120
D12.776.377 globuliny 68
D12.776.377.715 sérové globuliny 61
D12.776.377.715.548 imunoglobuliny 1 486
D12.776.377.715.548.114 protilátky 1 815
D12.776.377.715.548.114.071 protilátky anti-idiotypické 61
D12.776.377.715.548.114.071.500 omalizumab 112
D12.776.377.715.548.114.224 monoklonální protilátky 4 626
D12.776.377.715.548.114.224.200 humanizované monoklonální protilátky 2 783
D12.776.377.715.548.114.224.200.125 abciximab 14
D12.776.377.715.548.114.224.200.250 adalimumab 346
D12.776.377.715.548.114.224.200.375 alemtuzumab 123
D12.776.377.715.548.114.224.200.407 basiliximab 2
D12.776.377.715.548.114.224.200.438 bevacizumab 445
D12.776.377.715.548.114.224.200.469 brentuximab vedotin 40
D12.776.377.715.548.114.224.200.500 certolizumab pegol 47
D12.776.377.715.548.114.224.200.750 cetuximab 185
D12.776.377.715.548.114.224.200.766 daklizumab 6
D12.776.377.715.548.114.224.200.782 denosumab 150
D12.776.377.715.548.114.224.200.790 gemtuzumab 16
D12.776.377.715.548.114.224.200.794 inotuzumab ozogamicin 11
D12.776.377.715.548.114.224.200.798 ipilimumab 253
D12.776.377.715.548.114.224.200.813 natalizumab 156
D12.776.377.715.548.114.224.200.829 nivolumab 427
D12.776.377.715.548.114.224.200.844 omalizumab 112
D12.776.377.715.548.114.224.200.860 palivizumab 12
D12.776.377.715.548.114.224.200.864 panitumumab 57
D12.776.377.715.548.114.224.200.866 ramucirumab 1
D12.776.377.715.548.114.224.200.868 ranibizumab 61
D12.776.377.715.548.114.224.200.875 trastuzumab 268
D12.776.377.715.548.114.224.200.937 ustekinumab 120